Halil AŞCI, YONCA SÖNMEZ, Mustafa SAYGIN, Fatma Nihan CANKARA, Şükriye YEŞİLOT, Mustafa Kemal YILDIRIM

6024

Investigation of the presence of potential drug-drug interactions in the adult intensive care unit: a retrospective study

Amaç: Bu çalışmanın amacı, Üniversite Eğitim ve Araştırma Hastanesi Erişkin Yoğun Bakım Ünitesindeki hastalarda potansiyel ilaç-ilaç etkileşimleri türü ve sıklığı açıklamaktır. Gereç ve Yöntem: Bu çalışma Türkiye'de bulunan 18 yataklı erişkin Yoğun Bakım Ünitesine sahip Üniversite Eğitim ve Araştırma Hastanesinde yürütülmüştür. Çalışmaya Ocak 2013 ve Haziran 2013 tarihleri arasında yoğun bakım ünitesine yatırılan 111 hasta alınmıştır. İlaçlar anatomiksel kimyasal tedavi sınıflandırılmasına göre sıralanmıştır. Yoğun Bakım Ünitesine yatırılan 111 hasta çalışmaya dahil edildi. Potansiyel ilaç-ilaç etkileşimleri analizi için Lexi-Comp veritabanı kullanıldı.Bulgular: Altı aylık bir dönemde, 1681 potansiyel ilaç-ilaç etkileşimi toplam 102 (% 91.9) hastada belirlendi. 101 hastanın potansiyel ilaç-ilaç etkileşimlerinin en yaygın türü C tipidir (1232,% 73.2). Hastaların potansiyel ilaç-ilaç etkileşimleri ile polifarmasi varlığı, hastalık sayısı ve kalış süresi arasında anlamlı bir ilişki vardı. Potansiyel ilaçilaç etkileşimleri olan hastalarda meydana gelen ölümsayısı 68 (% 66.7) ve yoğun bakım ünitesinden taburcu edilen hasta sayısı 34 (% 33.3)' tür. D ve X-tipi potansiyel ilaç-ilaç etkileşimlerinin varlığı ile ilaçların sayısı ve yoğun bakımda kalış süresi arasında anlamlı bir ilişki vardı. Ayrıca ölüm oranı ile D-tipi ve X-tipi potansiyel ilaç-ilaç etkileşimleri arasında ilişki anlamlı derecede yüksekti. 49 (% 44.1) hastada adrenalin ve dopamin arasındaki etkileşim en sık görülen potansiyel ilaç-ilaç etkileşimleridir. Tartışma: Yoğun bakım hastalarında çoklu ilaç kullanımı ve hastalıkların sayısı; potansiyel ilaç-ilaç etkileşimleri ve polifarmasi görülme riskini, hastanede kalış süresini ve mortalite oranını artırmaktadır

Yetişkin yoğun bakım ünitesinde potansiyel ilaç-ilaç etkileşimleri varlığının araştırılması: Retrospektif bir çalışma

Aim: The goal of this study is to describe the type and frequency of potential drug-drug nteractions in patients in the adult Intensive Care Unit of Research and Education University Hospital.Material and Method: This study was carried out in the research and education university hospital 18-bed adult Intensive Care Unit in Turkey. The study included 111 hospitalized patients in the Intensive Care Unit between January 2013 and June 2013. The drugs were classified according to the anatomical therapeutic chemical classification. Analysis of potential drug-drug interactions was performed using Lexi-Comp database.Results: In a six-month period, 1681 potential drug-drug interactions were detected in 102 (91.9 %) patients. In 101 patients the most common type of potential drug-drug interactions was C type (1232, 73.2%). The presence of potential drug-drug interactions and polypharmacy in patients had a significant relationship with the number of drugs, the number of diseases and the length of stay. In patients with potential drug-drug interactions, death occured in 68 (66.7%) patients and 34 (33.3%) patients were discharged from the intensive care unit. The presence of D and X-type potential drug-drug interactions had a significant relationship with the between number of drugs used and the length of stay in the intensive care unit. Also death rate was significantly higher among D-type and X-type potential drug-drug interactions. Adrenaline and dopamine interactions were the most frequent potential drug-drug interactions in 49 (44.1%) patients. Discussions: In intensive care patients a multiple drug use and number of diseases increase potential drug-drug interactions, polypharmacy, the length of stay and the mortality rate. Additionally, the types of potential drug-drug interactions increased the same above mentioned parameter
PDF

___

  • 1. Bista D, Palaian S, Shankar PR, Prabhu MM, Paudel R, Mishra P. Understanding the essentials of drug interactions: a potential need for safe and effective use of drugs. Kathmandu Univ Med J. 2007;5(3):421-430.
  • 2. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003;21(3):153-158.
  • 3. Beers MH, Storrie M, Lee G. Potential adverse drug interactions in the emergency room. An issue in the quality of care. Ann Intern Med. 1990;112: 61-64.
  • 4. Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart-van Rijkom JE, Cremer OL et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy 2014;34(3):213- 219.
  • 5. Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014; 10(3): 920-932.
  • 6. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817-832.
  • 7. Lee A, Stockley IH. Drug interactions In: Walker R, Edwards C. Clinical Pharmacy and Therapeutics. 3rd edition. Churchill Livingstone, Philadelphia; 2003. p. 21-31.
  • 8. Flepisi BT, Bouic P, Sissolak G, Rosenkranz B.Drug-drug interactions in HIV positive cancer patients. Biomed Pharmacother. 2014;68(5):665-677.
  • 9. Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011;31(5): 309-316.
  • 10. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5): 691-98.
  • 11. Van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RH, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5): 1071- 1078.
  • 12. Farhoudi M, Khalili H, Karimzadeh I, Abbasian L.Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center. Expert Opin Drug Metab Toxicol. 2015;11(4):471-479.
  • 13. Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71(2):131-142.
  • 14. Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra Júnior DP, Pilger D,et al. Adverse drug reactions caused by drug-drug interactions in elderly outpatients: aprospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667-1676.
  • 15. Lexi-Interact™ Online. 2014, http://www.uptodate.com/ crlsql/interact/frameset.jsp, Accessed: December 05, 2015.
  • 16. Stoll P, Kopittke L. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospectivecohort study. Int J Clin Pharm. 2015;37(3):475-484.
  • 17. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J.Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol. 1997;53(1):7-11.
  • 18. Rossi A, Ganassini A, Tantucci C, Grassi V. Aging and the respiratory system. Aging (Milano). 1996;8(3):143- 61.
  • 19. Tavakoli-Ardakani M, Kazemian K, Salamzadeh J, Mehdizadeh M. Potential of drug interactions among hospitalized cancer patients in a developing country. Iran J Pharm Res. 2013; 2 (Suppl.):175-82.
  • 20. Araujo TE, Vieira SM, Carvalho PR. Stress ulcer prophylaxis in pediatric intensive care units. J Pediatr (Rio J). 2010;86(6):525-530.
  • 21. Haji Aghajani M, Sistanizad M, Abbasinazari M, Abiar Ghamsari M, Ayazkhoo L, Safi O, et al. Potential Drugdrug interactions in Post-CCU of a Teaching Hospital. Iran J Pharm Res. 2013;12(1):243-248.
  • 22. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-272.
  • 23. Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, GojoTomic N, Rahelic D. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci. 2010;32(6):815-21.
  • 24. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345.
  • 25. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-71.
  • 26. Ponte ML, Keller GA, Di Girolamo G. Mechanisms of Drug Induced QT Interval Prolongation. Curr Drug Saf. 2010;5(1): 44-53.
  • 27. Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104.e1-6.
  • 28. Chiang-Hanisko L, Tan JY, Chiang LC. Polypharmacy issues in older adults. Hu Li Za Zhi. 2014;61(3):97-104.
  • 29. Buijs EA, Reiss IK, Kraemer U, Andrinopoulou ER, Zwiers AJ, Ince C, et al. Increasing mean arterial blood pressure and heart rate with catecholaminergic drugs does not improve the microcirculation in children with congenital diaphragmatic hernia: a prospective cohort study. Pediatr Crit Care Med. 2014;15(4):343-54.
  • 30. Scappaticci KA, Ham JA, Sohn YJ, Miller RD, Dretchen KL. Effects of furosemide on the neuromuscular junction. Anesthesiology. 1982;57(5):381-388.
  • 31. Siebels M, Andrassy K, Vecsei P, Seelig HP, Back T, Nawroth P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res. 1992;66(5): 467-73.
  • 32. Kosar A, Cipil HS, Kaya A, Uz B, Haznedaroglu IC, Goker H, et al. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model. Blood Coagul Fibrinolysis. 2009;20(3):185-190.
  • 33. Okulicz-Kozaryn I, Leppert W, Mikolajczak P, Kaminska E. Analgesic effects of tramadol in combination with adjuvant drugs: an experimental study in rats. Pharmacology. 2013;91(1-2):7-11.
  • 34. Worthley LI. Clinical toxicology: part I. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215.
  • 35. Chang KY, Lee IH, Kim GJ, Cho K, Park HS, Kim HW. Plasma exchange successfully treats central pontine myelinolysis after acute hypernatremia from intravenous sodium bicarbonate therapy. BMC Nephrol. 2014;15:56.
  • 36. Brater DC, Kaojarern S, Benet LZ, Lin ET, Lockwood T, Morris RC, et al. Renal excretion of pseudoephedrine. Clin Pharmacol Ther. 1980;28(5):690-69.
  • 37. Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;Suppl.G:5-9.
  • 38. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57(7):3060-3066.
  • 39. Rasmussen LE, Nedergaard OA. Effects of reboxetine on sympathetic neuroeffector transmission in rabbit carotid artery. J Pharmacol Exp Ther. 2003;306(3):995- 1002.
  • 40. Craft RM, Ulibarri CM, Raub DJ. Kappa opioid-induced diuresis in female vs. male rats. Pharmacol Biochem Behav. 2000;65(1):53-59.
  • 41. Edwards RT, McCormick-Deaton C, Hosanagar A. Acute urinary retention secondary to buprenorphine administration. Am J Emerg Med. 2014;32(1):109.e1-2.
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi-Cover
  • ISSN: 1300-7416
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1994
  • Yayıncı: SDÜ Basımevi / Isparta
Arşiv
Sayıdaki Diğer Makaleler

Antioksidan redoks sistemi üzerinde metallotionin ve çinko ilişkisinin önemi

Betül YAZĞAN, Yener YAZĞAN

Nörogelişimsel psikiyatrik bozuklukların doğum mevsimi ile ilişkisinin incelenmesi

Sevcan KARAKOÇ DEMİRKAYA, Hatice AKSU, Kutay TAŞ, Börte Gürbüz ÖZGÜR

Geç yaşta saptanan bir pulmoner konjenital anomali olgusu - konjenital kistik adenomatoid malformasyon

Zahide ALAÇAM, Neşe DURSUNOĞLU, Furkan UFUK, ERHAN UĞURLU, Ali İhsan YILDIZ

Retinal ven tıkanıklığında kombine İntravitreal triamsinolon asetonid-bevacizumab tedavisinin kısa dönem etkisi

Handan BARDAK, MURAT GÜNAY, Hatice DALDAL, Yavuz BARDAK

Investigation of the presence of potential drug-drug interactions in the adult intensive care unit: a retrospective study

Halil AŞCI, YONCA SÖNMEZ, Mustafa SAYGIN, Fatma Nihan CANKARA, Şükriye YEŞİLOT, Mustafa Kemal YILDIRIM

Nüks spontan pnömotoraks olgusunda tek port video yardımlı torakoskopik cerrahi deneyimimiz:olgu sunumu

Yücel AKKAŞ, Mehmet Ali ERYAZGAN, Bülent KOÇER, Rasih YAZKAN